Denmark calls for fair treatment of Novo Nordisk as US eyes insulin price cap

President Joe Biden and a number of senators are trying to cap insulin prices in the US, and Denmark’s minister of foreign affairs is hoping that potentially affected Danish firms will be treated fairly.

Jeppe Kofod, Minister of Foreign Affairs of Denmark | Photo: Thomas Borberg

US Democrats are still trying to pass a bill that would cap diabetes patients’ out-of-pocket insulin expenses in the country.

Should it pass, the legislation could impact insulin makers supplying the US, including Novo Nordisk, Eli Lilly, and Sanofi, which are behind 90% of insulin sales in the US.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs